Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Add To Watchlist

Recent & Breaking News (GREY:ADXS)

Advaxis's Listeria-based Lm-LLO Immunotherapy Featured in Nature Biotechnology

GlobeNewswire December 11, 2014

Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-PSA in Combination With Merck's KEYTRUDA(R) (pembrolizumab) for Prostate Cancer

GlobeNewswire December 8, 2014

InMed Pharma's Hiring of Tiberend Highlights Biotech Focus

Accesswire December 3, 2014

Advaxis to Present at the LD Micro Conference

GlobeNewswire November 25, 2014

MarketExclusive.com - Nobel Financial Reiterates Buy Rating of Advaxis, Inc. Based on a Review of Recent Data Presentations and IND Submissions

Accesswire November 24, 2014

Advaxis, Inc. - "From Two Checkpoint Inhibitor Development Agreements to Two IND Filings in Four Months - A Special Thanks..."

Accesswire November 24, 2014

Advaxis to Receive $1.7M Through New Jersey Technology Business Tax (NOL) Program

GlobeNewswire November 20, 2014

Advaxis Submits Investigational New Drug Application for Phase 1/2 Study of ADXS-HPV and MedImmune's MEDI4736 for the Treatment of HPV-Associated Cervical and Head & Neck Cancer

GlobeNewswire November 12, 2014

Advaxis Submits Investigational New Drug Application for ADXS31-142 (ADXS-PSA) for the Treatment of Metastatic Castration Resistant Prostate Cancer

GlobeNewswire November 5, 2014

Advaxis to Present Survival Data of Lm-LLO Cancer Immunotherapies in Recurrent Cervical Cancer and Canine Osteosarcoma at the Society for Immunotherapy of Cancer 29th Annual Meeting

GlobeNewswire November 4, 2014

Advaxis's ADXS-cHER2 Immunotherapy Demonstrates T-Cell Immune Response in Data Analysis From Canine Osteosarcoma Study

GlobeNewswire October 30, 2014

Advaxis, Inc. - "Adding the Right Players, Right Positions at the Right Time"

Accesswire October 22, 2014

Advaxis Appoints David J. Mauro, M.D., Ph.D., as Chief Medical Officer

GlobeNewswire October 20, 2014

Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer

GlobeNewswire October 15, 2014

Advaxis's Lm-LLO Immunotherapy Data to be Presented in Three Posters at the Society for Immunotherapy of Cancer 29th Annual Meeting

GlobeNewswire October 14, 2014

Advaxis Appoints World Renowned Oncologist and Research Scientist, Dr. Samir N. Khleif, to Its Board of Directors

GlobeNewswire October 8, 2014

Advaxis's Chief Scientific Officer, Dr. Robert Petit, Leads Panel Discussion on Combination Immunotherapies

GlobeNewswire October 1, 2014

Advaxis's Cancer Immunotherapy Featured on Fox News

GlobeNewswire September 26, 2014

Advaxis, Inc. "Changing Seasons - but not direction. Where's Advaxis headed as summer becomes fall?"

Accesswire September 22, 2014

Advaxis Provides a Clinical Development Update for Its Immunotherapy, ADXS-HPV, for the Treatment of Cervical Cancer

GlobeNewswire September 9, 2014